JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon (NYSE: OGN), a global women’s health company, today announced clearance by the U.S. Food and Drug Administration (FDA) of the Special 510(k) for ...
The JADA ® System for treatment of abnormal postpartum uterine bleeding, and the team behind the product, join Laborie, strengthening the company's commitment to improving maternal health. Joining an ...
Net proceeds will be applied to debt reduction, advancing Organon’s ongoing deleveraging efforts Positions Organon for future investment in growth opportunities with a focus on women’s health ...
The JADA ® System is intended to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted. Organon (NYSE: OGN) is a global ...
Organon (OGN) shares added ~3% in the premarket on Monday, even as the women’s health company lowered its full-year outlook despite better-than-expected Q3 2025 financials amid its plans to divest the ...
The MarketWatch News Department was not involved in the creation of this content. The JADA(R) System for treatment of abnormal postpartum uterine bleeding, and the team behind the product, join ...
The JADA ® System is intended to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted. Avoid excessive force when inserting ...
(MENAFN- AETOSWire) (BUSINESS WIRE )--Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, announced today the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results